Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analytical performance of cervista HPV 16/18 in SurePath pap specimens.

Diagnostic cytopathology - 1 Apr 2015

Guo Ming, Khanna Abha, Feng Jie, Patel Shobha, Zhang Wei, Gong Yun, Huo Lei, Staerkel Gregg

Abstract excerpt

BACKGROUND: To evaluate the performance of Cervista HPV 16/18 in SurePath specimens, we compared the analytical sensitivity of Cervista HPV 16/18 with that of a previously validated PCR-based, commercially available HPV genotyping assay, EasyChip HPV Blot, in residual specimens collected after routine Pap tests at our cancer center. METHODS: We retrospectively selected 79 consecutive Cervista HPV HR (high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervix Uteri
Share to Cohort Studies
Share to Human papillomavirus 16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Human papillomavirus 18

Share to Papanicolaou Test

Share to Papillomavirus Infections

Share to Predictive Value of Tests

Share to Uterine Cervical Dysplasia

Source

Identifiers

PMID: 25352375
DOI: 10.1002/dc.23221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical performance of cervista HPV 16/18 in SurePath pap specimens.PMID 25352375Read ↗

Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.Semantic proximity Read ↗

Comparative evaluation of AMPLICOR HPV PCR and Linear Array assays on SurePath liquid-based Pap samples for the detection of high-risk HPV genotypes.Semantic proximity Read ↗

Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.Semantic proximity Read ↗

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the International Guidelines for Human Papillomavirus Test Requirements for Cervical ScreeningSemantic proximity Read ↗

Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples.Semantic proximity Read ↗

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.Semantic proximity Read ↗

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.Semantic proximity Read ↗

Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.Semantic proximity Read ↗

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.Semantic proximity Read ↗

Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.Semantic proximity Read ↗

Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.Semantic proximity Read ↗

Evaluation of the SureX HPV Genotyping Test for the Detection of High-Risk HPV in Cervical Cancer ScreeningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.